Research ExplorerPublicationsAtrial fibrillation in women: treatment

Atrial fibrillation in women: treatment

Standard

Atrial fibrillation in women: treatment. / Ko, Darae; Rahman, Faisal; Martins, Maria A P; Hylek, Elaine M; Ellinor, Patrick T; Schnabel, Renate B; Benjamin, Emelia J; Christophersen, Ingrid E.

In: NAT REV CARDIOL, Vol. 14, No. 2, 02.2017, p. 113-124.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Ko, D, Rahman, F, Martins, MAP, Hylek, EM, Ellinor, PT, Schnabel, RB, Benjamin, EJ & Christophersen, IE 2017, 'Atrial fibrillation in women: treatment', NAT REV CARDIOL, vol. 14, no. 2, pp. 113-124. https://doi.org/10.1038/nrcardio.2016.171

APA

Ko, D., Rahman, F., Martins, M. A. P., Hylek, E. M., Ellinor, P. T., Schnabel, R. B., Benjamin, E. J., & Christophersen, I. E. (2017). Atrial fibrillation in women: treatment. NAT REV CARDIOL, 14(2), 113-124. https://doi.org/10.1038/nrcardio.2016.171

Vancouver

Ko D, Rahman F, Martins MAP, Hylek EM, Ellinor PT, Schnabel RB et al. Atrial fibrillation in women: treatment. NAT REV CARDIOL. 2017 Feb;14(2):113-124. https://doi.org/10.1038/nrcardio.2016.171

Bibtex

@article{240c53808e48456dbd9cc99dc6084311,
title = "Atrial fibrillation in women: treatment",
abstract = "Sex-specific differences in the epidemiology, pathophysiology, presentation, prognosis, and treatment of atrial fibrillation (AF) are increasingly recognized. Women with AF generally experience worse symptoms, poorer quality of life, and have higher risk of stroke and death than men with AF. Effective treatment of the arrhythmia in women is critical to reduce the rate of adverse events. We review the current evidence on sex-specific differences in the utilization and outcomes of treatments for AF, including rate-control and rhythm-control strategies, and stroke-prevention therapy. In addition, we provide a critical evaluation of potential disparities and biases in health-care use that might be associated with differences in the outcomes between women and men. We underscore current knowledge gaps that need to be addressed in future studies to improve the management of AF in women. In particular, we suggest several strategies to produce high-quality evidence from randomized clinical trials for women with AF.",
keywords = "Atrial Fibrillation/epidemiology, Female, Humans, Patient Care Management/methods, Prognosis, Quality of Life, Sex Factors",
author = "Darae Ko and Faisal Rahman and Martins, {Maria A P} and Hylek, {Elaine M} and Ellinor, {Patrick T} and Schnabel, {Renate B} and Benjamin, {Emelia J} and Christophersen, {Ingrid E}",
year = "2017",
month = feb,
doi = "10.1038/nrcardio.2016.171",
language = "English",
volume = "14",
pages = "113--124",
journal = "NAT REV CARDIOL",
issn = "1759-5002",
publisher = "NATURE PUBLISHING GROUP",
number = "2",

}

RIS

TY - JOUR

T1 - Atrial fibrillation in women: treatment

AU - Ko, Darae

AU - Rahman, Faisal

AU - Martins, Maria A P

AU - Hylek, Elaine M

AU - Ellinor, Patrick T

AU - Schnabel, Renate B

AU - Benjamin, Emelia J

AU - Christophersen, Ingrid E

PY - 2017/2

Y1 - 2017/2

N2 - Sex-specific differences in the epidemiology, pathophysiology, presentation, prognosis, and treatment of atrial fibrillation (AF) are increasingly recognized. Women with AF generally experience worse symptoms, poorer quality of life, and have higher risk of stroke and death than men with AF. Effective treatment of the arrhythmia in women is critical to reduce the rate of adverse events. We review the current evidence on sex-specific differences in the utilization and outcomes of treatments for AF, including rate-control and rhythm-control strategies, and stroke-prevention therapy. In addition, we provide a critical evaluation of potential disparities and biases in health-care use that might be associated with differences in the outcomes between women and men. We underscore current knowledge gaps that need to be addressed in future studies to improve the management of AF in women. In particular, we suggest several strategies to produce high-quality evidence from randomized clinical trials for women with AF.

AB - Sex-specific differences in the epidemiology, pathophysiology, presentation, prognosis, and treatment of atrial fibrillation (AF) are increasingly recognized. Women with AF generally experience worse symptoms, poorer quality of life, and have higher risk of stroke and death than men with AF. Effective treatment of the arrhythmia in women is critical to reduce the rate of adverse events. We review the current evidence on sex-specific differences in the utilization and outcomes of treatments for AF, including rate-control and rhythm-control strategies, and stroke-prevention therapy. In addition, we provide a critical evaluation of potential disparities and biases in health-care use that might be associated with differences in the outcomes between women and men. We underscore current knowledge gaps that need to be addressed in future studies to improve the management of AF in women. In particular, we suggest several strategies to produce high-quality evidence from randomized clinical trials for women with AF.

KW - Atrial Fibrillation/epidemiology

KW - Female

KW - Humans

KW - Patient Care Management/methods

KW - Prognosis

KW - Quality of Life

KW - Sex Factors

U2 - 10.1038/nrcardio.2016.171

DO - 10.1038/nrcardio.2016.171

M3 - SCORING: Review article

C2 - 27786235

VL - 14

SP - 113

EP - 124

JO - NAT REV CARDIOL

JF - NAT REV CARDIOL

SN - 1759-5002

IS - 2

ER -